Early Stage Drug Discovery
Witnessing the Birth of a New Generation of Pharmacological Degraders
From in silico prediction…
The PPI-FIT technology allows the exploration of unique pharmacological targets represented by protein folding intermediates. This innovation places Sibylla Biotech in the exclusive position of identifying compounds with a mechanism of action that has never been explored.
To this aim, we have developed ad-hoc virtual screening workflows to identify small molecules targeting pockets on the intermediate folding states. Depending on the project, hit identification is carried out using different types of virtual chemical libraries or partners’ proprietary libraries.
… to biological characterization
Our ongoing experience with the technology is driving the way we analyze PPI-FIT molecules. Indeed, since the method acts on folding intermediates, our experimental investigation is tailored to detect effects at the level of nascent protein chains by relying on cell-based and biochemical/biophysical assays. Next, we employ context-dependent, disease-relevant assays to evaluate the therapeutic potentials of each individual hit.
Developing Characterized Hits Towards Optimized Leads
Cutting Edge Rational Drug Design Approaches
Sibylla employs classical computational tools in combination with newly implemented AI-based algorithms to drive the optimization of the characterized hits. Such machine- learning approaches are developed by our medicinal chemistry team and can be used to predict various features of the molecules, such as potency or ADME properties.
Sibylla targets the Pharma industries’ need for out-sourcing discovery and preclinical studies through collaboration partnerships.
We may work in collaboration with Pharmaceutical and Biotech companies.
We can apply the PPI-FIT protocol to targets of their interest, delivering the identification of new druggable pockets identified on the folding intermediate state, virtual hits, identified hits on cell-based assays, and in-silico chemical optimization.